ArticleFrontiers in pharmacology2025
The mechanistic role of gitogenin as a treatment for laryngeal cancer: a network pharmacology and experimental analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Laryngeal cancer (LC) is a significant and persistent therapeutic challenge worldwide. Gitogenin (GIT), a naturally occurring saponin, has demonstrated anticancer activity in lung cancer. However, its potential effects on LC remain unclear. This study aimed to elucidate the therapeutic efficacy of GIT and the mechanisms through which it acts against LC by integrating network pharmacology analysis with experimental validation. Methods: Potential targets of GIT were established using the PharmMapper database, while LC-associated genes were retrieved from the GeneCards database. Common targets between GIT and LC were determined, and the top 20 genes were chosen for protein-protein and gene-gene interaction (PPI and GGI) network construction. Functional enrichment analyses were conducted. Finally, Results: A total of 96 putative GIT targets for LC were identified. KEGG enrichment identified the PI3K-Akt axis a key regulatory mechanism. Conclusion: Using network pharmacology and experimental validation, it was demonstrated that GIT exerts potent anticancer effects on LC by targeting the PI3K-Akt axis. The present findings suggest the potential of GIT for treating LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.